Lenalidomide Accord (Lenalidomide)

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

• Multiple myeloma: improves progression‑free and overall survival when combined with dexamethasone or other agents.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves blood counts.
• Mantle cell lymphoma (relapsed/refractory): provides clinical benefit as part of combination therapy.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination of transcription factors such as Ikaros and Aiolos. This leads to reduced proliferation of malignant plasma cells, enhanced immune‑mediated tumor cell clearance, and inhibition of angiogenesis, collectively contributing to its antineoplastic activity.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Neutropenia: lowered neutrophil count increasing infection risk.
• Thrombocytopenia: reduced platelet count, may cause easy bruising.
• Diarrhea: loose stools, sometimes leading to dehydration.
• Constipation: difficulty passing stool.
• Rash: mild skin irritation or redness.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: markedly low neutrophils requiring medical intervention.
• Severe thrombocytopenia: dangerously low platelets with bleeding risk.
• Secondary primary malignancies: emergence of new cancers.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Lenalidomide requires careful monitoring and specific safety measures.

• Pregnancy contraindication: teratogenic; ensure effective contraception for both patient and partner.
• Thrombosis risk: assess need for prophylactic anticoagulation, especially with additional risk factors.
• Hematologic monitoring: regular CBCs to detect neutropenia or thrombocytopenia.
• Renal impairment: dose adjustment may be needed in patients with reduced kidney function.
• Drug interaction vigilance: avoid concurrent use with strong CYP3A4 inhibitors without supervision.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
• Thalidomide: additive teratogenic and hematologic toxicity.
• Anticoagulants (e.g., warfarin): heightened risk of thromboembolic events.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.
• Live vaccines: immunosuppression can diminish vaccine response.
• NSAIDs: may increase risk of renal impairment when combined with lenalidomide.